NCT00170742终止3 期
A Randomized, Open Label, Controlled Study on the Efficacy and Safety of Octreotide i.m. in Patients With Proliferative Diabetic Retinopathy (PDR) After Start of Laser Coagulation
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- Novartis
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- regression of neovascularization.
研究概览
简要总结
Phase III study comparing monthly octreotide i.m. in comparison to no additional treatment in patients with proliferative diabetic retinopathy after lasercoagulation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with type-I or type-II-diabetes mellitus.
- •Males or females aged 18 - 70 years.
- •Proliferative diabetic retinopathy (PDR) in at least one eye that has an ETDRS visual acuity score > 35 letters (20/200 or better), and that has no other condition that might interfere with assessment of retinopathy progression (see exclusion criterion #1).
- •Media clarity, pupillary dilation and patient cooperation sufficient to allow stereoscopic 30°, or equivalent, fundus photographs of adequate quality in at least one eye that meets criterion #3 above.
- •Starting of photocoagulation of at least one eye to treat PDR in between approximately 2 weeks prior to start of study.
- •HbA1c < 13.0% at study entry. In addition, patients must be capable of testing their blood glucose levels at home and adjusting their insulin dosage to maintain blood glucose control.
- •Systolic blood pressure < 180 mm Hg and diastolic blood pressure < 105 mm Hg at study entry.
- •Females of childbearing potential must:
- •Have a negative pregnancy test prior to study entry.
- •Be practicing acceptable birth control measures inclusive of intrauterine devices or mechanical methods (i.e., oral contraceptives, vaginal diaphragm, vaginal sponge or condom with spermicide).
- •Ability to read, understand and write German language
- •Patients must give written informed consent to participate in this study.
排除标准
- •Pretreatment as panretinal laser treatment other than photocoagulation which started approximately 2 weeks prior to start of study (see inclusion criteria # 5).
- •Patients in whom the only otherwise eligible eye has, in the opinion of the investigator or of the central fundus photograph reading center, a condition that might interfere with assessment of retinopathy progression, including optic atrophy, extensive healed chorioretinitis, retinopathy that appears to have regressed spontaneously (with or without traction retinal detachment), retinal vascular occlusion, retinal degeneration, or other abnormality.
- •Patients with a history of symptomatic gallstones who have not had a cholecystectomy (patients with asymptomatic cholelithiasis may be entered).
- •Patients with brittle diabetes, type-I diabetes who have frequent decompensations in their glycemic control, with recurrent ketoacidosis or hypoglycemia that significantly interferes with their lifestyle.
- •Patients with a history of severe hypoglycemia unawareness.
- •Patients with a significant medical condition, other than diabetes mellitus, which may interfere with the evaluation of safety or efficacy of the study compound (e.g., unstable angina pectoris, myocardial infarction within 3 months prior to study entry, severe renal failure, patients on renal dialysis, patients who have received a renal transplant).
- •Patients who have received any investigational drug within 4 weeks prior to study entry.
- •Patients who have received prior treatment with Sandostatin or any other somatostatin analogue.
- •History of non-compliance to medical regimens or who are considered potentially unreliable Other protocol-defined inclusion/exclusion criteria may apply.
结局指标
主要结局
regression of neovascularization.
次要结局
- Determine tolerability and safety
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled AcromegalyAcromegalyNCT00372697Novartis Pharmaceuticals28
尚未招募
3 期
Octreotide drug compared with diet Restriction in treating Chyle Leak in Head and Neck Cancer PatientsCTRI/2024/03/063582Tata Memorial Centre
已完成
2 期
Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer PatientsProstate CancerNCT00166725Novartis40
已完成
3 期
A Phase 3b, open-label treatment extension study of upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who completed treatment in Study M16-046Eczema1000381610014982Atopic DermatitisNL-OMON55265AbbVie Deutschland GmbH & Co. KG15
Unknown
2 期
Octreotide in Patients With GI Bleeding Due to Rendu-Osler-WeberGastrointestinal HemorrhageAnemiaHereditary Hemorrhagic TelangiectasiaNCT02874326Radboud University Medical Center15